Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01034163 | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)(PATH) | completed | Phase 3 | 41 | Novartis PharmaceuticalsINDUSTRY | 14 | Jul 7, 2016 | clinicaltrials |
| NCT00006348 | Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment | completed | Phase 3 | 100 | Alliance for Clinical Trials in OncologyOTHER |
| 1 |
| Jul 6, 2016 |
| clinicaltrials |
| NCT00327678 | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | completed | Phase 3 | 1,080 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 27, 2016 | clinicaltrials |
| NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | completed | Phase 2 / Phase 3 | 47 | Tampere University HospitalOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT01324596 | A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib(REMoDL-B) | completed | Phase 3 | 1,132 | University Hospital Southampton NHS Foundation TrustOTHER | 2 | Apr 15, 2016 | clinicaltrials |
| NCT00123760 | Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer | completed | Phase 2 / Phase 3 | 10,838 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01530594 | Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 440 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00002766 | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma | completed | Phase 3 | 170 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01892618 | Pneumococcal Vaccine in Untreated CLL Patients | completed | Phase 3 | 134 | Karolinska University HospitalOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT02569996 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | completed | Phase 3 | 124 | Hoffmann-La RocheINDUSTRY | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | completed | Phase 3 | 668 | University of ArkansasOTHER | 1 | Nov 23, 2015 | clinicaltrials |
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | completed | Phase 3 | 212 | Gary MorrowOTHER | 3 | Nov 11, 2015 | clinicaltrials |
| NCT01160315 | Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure(Erasme-POF) | completed | Phase 2 / Phase 3 | 118 | Erasme University HospitalOTHER | 3 | Oct 30, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT01621672 | UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | completed | Phase 3 | 42 | University of ArkansasOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00111748 | UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | completed | Phase 3 | 180 | University of ArkansasOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT00217438 | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | completed | Phase 3 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00566332 | Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia | completed | Phase 3 | 414 | French Study Group on Chronic Lymphoid LeukemiaNETWORK | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01251107 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | completed | Phase 3 | 331 | Fondazione MichelangeloOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01014208 | Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma(ORCHARRD) | completed | Phase 3 | 447 | GlaxoSmithKlineINDUSTRY | 26 | Aug 7, 2015 | clinicaltrials |
| NCT00269113 | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | completed | Phase 3 | 360 | Hoffmann-La RocheINDUSTRY | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00003414 | Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease | completed | Phase 3 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00398411 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells(MoxiProph) | completed | Phase 3 | 66 | University of CologneOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00117598 | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)(OPTIMAL) | completed | Phase 3 | 169 | PfizerINDUSTRY | 18 | Mar 30, 2015 | clinicaltrials |
| NCT00434161 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | completed | Phase 3 | 281 | Swedish Orphan BiovitrumINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00064038 | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 3 | 198 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00838357 | A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).(PREDICT) | completed | Phase 3 | 118 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Mar 24, 2015 | clinicaltrials |
| NCT00002548 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | completed | Phase 3 | 899 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416273 | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 217 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416208 | Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | completed | Phase 3 | 154 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01767714 | Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation | completed | Phase 3 | 100 | SanofiINDUSTRY | 1 | Dec 9, 2014 | clinicaltrials |
| NCT02288741 | Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy(DSMM-II) | completed | Phase 3 | 549 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Nov 11, 2014 | clinicaltrials |
| NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | completed | Phase 3 | 50 | OncotherapeuticsINDUSTRY | 1 | Nov 6, 2014 | clinicaltrials |
| NCT00795756 | Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 145 | Northern Italy Leukemia GroupOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT00059839 | Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma | completed | Phase 3 | 129 | Children's Oncology GroupNETWORK | 5 | Sep 22, 2014 | clinicaltrials |
| NCT00109031 | Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | completed | Phase 3 | 47 | Swedish Orphan BiovitrumINDUSTRY | 0 | Sep 15, 2014 | clinicaltrials |
| NCT01609010 | A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma | completed | Phase 3 | 313 | Hoffmann-La RocheINDUSTRY | 3 | Sep 8, 2014 | clinicaltrials |
| NCT00583323 | Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET | completed | Phase 3 | 60 | Mayo ClinicOTHER | 0 | Aug 21, 2014 | clinicaltrials |
| NCT00854568 | Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL | completed | Phase 3 | 398 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00813150 | Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma | completed | Phase 3 | 96 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Aug 15, 2014 | clinicaltrials |
| NCT00002618 | Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma | completed | Phase 3 | 242 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00002757 | TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma | completed | Phase 3 | 1,148 | Children's Oncology GroupNETWORK | 2 | Jul 24, 2014 | clinicaltrials |
| NCT00005578 | Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease | completed | Phase 3 | 219 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00139841 | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab | completed | Phase 3 | 103 | CephalonINDUSTRY | 3 | May 9, 2014 | clinicaltrials |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone(UPFRONT) | completed | Phase 3 | 502 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 1, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2016source: clinicaltrials